The overall alarming increase in case numbers over the last two decades is partly explained by a change in national practices to record and report dengue to the Ministries of Health, and to the WHO.
However, the data is not yet complete and COVID-19 pandemic might have also hampered case reporting in several The total number of cases seemingly decreased during years 20, as well as for reported deaths. Reported deaths between the year 20 increased from 960 to 4032,Īffecting mostly younger age group. The number of dengue cases reported to WHO increased over 8 fold over the last two decades, from 505,430 cases in 2000, to over 2.4 million in 2010, and 5.2 million in 2019. Despite a risk of infection existing in 129 countries, 70% of the actual burden is in Asia. The prevalence of dengue estimates that 3.9 billion people are at risk of infection with dengue viruses. One modelling estimate indicates 390 million dengue virus infections per year (95% credible interval 284–528 million), of which 96 million (67–136 million) manifest clinically (with any severity of disease). A vast majority of cases are asymptomatic or mild and self-managed, and hence the actual numbers of dengue cases are under-reported. The incidence of dengue has grown dramatically around the world in recent decades. DENV is frequently transported from one place to another by infected travellers when susceptible vectors are present in these new areas, there is the potential for local transmission to be established. Dengue has an alarming impact on both human healthĪnd the global and national economies. These can co-circulate within a region, and indeed many countries are hyper-endemic for all four serotypes. Subsequent infections (secondary infection) by other serotypes increase the risk of developing severe dengue.ĭengue has distinct epidemiological patterns, associated with the four serotypes of the virus. However, cross-immunity to the other serotypes after recovery is only partial, and temporary. Recovery from infection is believed to provide lifelong immunity against
Today, severe dengue affects most Asian and Latin American countries and has become a leading cause of hospitalization and death among children and adults in these regions.ĭengue is caused by a virus of the Flaviviridae family and there are four distinct, but closely related, serotypes of the virus that cause dengue (DENV-1, DENV-2, DENV-3 and DENV-4). Severe dengue was first recognized in the 1950s during dengue epidemics in the PhilippinesĪnd Thailand. Severe dengue has a higher risk of death when not managed appropriately. Of complications associated with severe bleeding, organ impairment and/or plasma leakage. Although less common, some people develop severe dengue, which can be any number This can range from subclinical disease (people may not know they are even infected) to severe flu-like symptoms in those infected. Dengue is widespread throughout the tropics, with local variations in risk influenced by climate parameters as well as social and environmental factors.ĭengue causes a wide spectrum of disease. Mosquitoes are also vectors of chikungunya, yellow fever and Zika viruses. Dengue virus is transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, Ae. Occasionally this develops into a potentially lethal complication, called severe dengue.ĭengue is a mosquito-borne viral disease that has rapidly spread to all regions of WHO in recent years. While many DENV infections produce only mild illness, DENV can cause an acute flu-like illness.Sustained community involvement can improve vector control efforts substantially. Dengue prevention and control depends on effective vector control measures.Although an estimated 100-400 million infections occur each year, over 80% are generally mild and asymptomatic. The global incidence of dengue has grown dramatically with about half of the world's population now at risk.
0 kommentar(er)
